Therapy of ulcerative colitis: State of the art

Current Opinion in Gastroenterology

Volumn 24, Issue 4, 2008, Pages 469-474

  Brain, Oliver ^a   Travis, Simon P L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Clinical trials; Review; Treatment; Ulcerative colitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALLOPURINOL; AZATHIOPRINE; BETA INTERFERON; CD20 ANTIBODY; CD3 ANTIBODY; CYCLOSPORIN A; DRUG METABOLITE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLMERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PHOSPHATIDYLCHOLINE; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PROBIOTIC AGENT; RITUXIMAB; STEROID; TACROLIMUS; TETOMILAST; TIOGUANINE; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

ABSCESS; ADAPTIVE IMMUNITY; ALTERNATIVE MEDICINE; ASPERGILLOSIS; BACTERIAL PNEUMONIA; BRONCHOPNEUMONIA; CELLULAR IMMUNITY; CLINICAL TRIAL; COLITIS; COLON RESECTION; DOSAGE SCHEDULE COMPARISON; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; ESCHERICHIA COLI INFECTION; FEMALE INFERTILITY; FUNGEMIA; HUMAN; ILEOANAL ANASTOMOSIS; ILEUM POUCH; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MULTIPLE SCLEROSIS; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; OSTEOMYELITIS; PATIENT COMPLIANCE; PNEUMONIA; PRACTICE GUIDELINE; PROGNOSIS; REMISSION; REVIEW; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SEPTICEMIA; T CELL LYMPHOMA; T LYMPHOCYTE; TABLET FORMULATION; TUBERCULOSIS; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; COLECTOMY; COLITIS, ULCERATIVE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS;

EID: 67449103746     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3282ff0dd5     Document Type: Review

References (63)

1. Ghosh S, Mitchell R. Results of the European Federation of Crohn's and Colitis Associations (EFCCA) patient survey: prevalence and impact on quality of life. J Crohn's Colitis (in press).
2. Dignass A, Vermeire S, Adamek H, et al. Improved remission rates from once-versus twice-daily mesalazine (Pentasa®) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial [abstract]. Gut 2007; 56 (Suppl III):A46.
3. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132:66-75. 4 Lichtenstein G, Kamm M, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5:95-102.
4. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007; 26:205-215.
5. TM mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 13 February [Epub ahead of print].
6. Kruis W, Gorelov A, Kiudelis G, et al. Once daily dosing of 3g mesalamine (Salofalk® granules) is therapeutic equivalent to a three-times daily dosing of 1 g mesalamine for the treatment of active ulcerative colitis [abstract]. Gastroenterology 2007; 132 (Suppl 4):A-130.
7. HanauerSB, Sandborn WJ, DallaireC, et al. Delayed-releaseoral mesalamine 4.8g/day (800 mg tablets) compared to 2.4g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007; 21:827-834.
8. Safdi AV, Cohen RD. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Aliment Pharmacol Ther 2007; 26:1179-1186.
9. Eliakim R, Tulassay Z, Kupcinskas L, et al. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. Aliment Pharmacol Ther 2007; 26:1237-1249.
10. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; (1):CD000478.
11. Chande N, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; (4):CD006618.
12. Yip JS, Woodward M, Abreu MT, Sparrow MP. How are azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. Inflamm Bowel Dis 2008; 14:514-518.
13. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007; 5:209-214.
14. Palaniappan S, Ford AC, Greer D, et al. Mycophenolate mofetil therapy for refractory inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:1488-1492.
15. Sandborn WJ, Rutgeerts P, Feagan BG, etal. Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: colectomy analysis from ACT1 and ACT 2 [abstract]. Gut 2007; 56 (Suppl III):A26.
16. Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007; 25:1055-1060.
17. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13:123-128.
18. Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007; 13:2328-2332.
19. Turner D, Walsh C, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5:103-110.
20. Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 2006; 40:476-481.
21. Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007; 26:411 -419.
22. Maser EA, Deconda D, LichtigerS, et al. Cyclosporine and infliximab as acute salvage therapies for each other, in severe steroid-refractory ulcerative colitis [abstract]. Gastroenterology 2007; 132 (Suppl 2):A-180.
23. Turner D, Otley AR, MackD, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007; 133:423-432.
24. Turner D, Walsh CM, Benchimol EI, et al. Severe paediatric ulcerative colitis: incidence, outcomes, and optimal timing for second line therapy. Gut 2008; 57:331-338. 26 Medress Z, Fleshner PR. Can we predict unplanned hospital readmission after colectomy for ulcerative colitis and indeterminate colitis? Am Surg 2007; 73:998-1001.
25. Scarpa M, Ruffolo C, Polese L, et al. Quality of life after restorative proctocolectomy for ulcerative colitis: different questionnaires lead to different interpretations. Arch Surg 2007; 142:158-165.
26. Maser EA, Present DH. Pouch-ouch. Curr Opin Gastroenterol 2008; 24:70-74.
27. Cornish JA, Tan E, Teare J, et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum 2007; 50:1128-1138.
28. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44:265-267.
29. Caspersen S, Elkjaer M, Riis L, et al. Infliximab treatment in inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow up on malignancy and mortality. Clin Gastroenterol Hepatol (in press).
30. Lichtenstein GR, Cohen RD, Feagan BF, et al. Safety of infliximab and other Crohn's disease therapies: TREAT registry data with nearly 20000 patient-years of follow-up [abstract]. Gastroenterology 2007; 132:A178.
31. Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 2007; 56:1181-1183.
32. Van Assche G, Paintaud G, D'Haens G, et al. Continuation of immunosuppression is not required to maintain adequate infliximab efficacy in patients with Crohn's disease but may improve pharmacokinetics [abstract]. Gastroenterology 2006; 130:A142.
33. Reindl W, Schmid RM, Huber W. Cyclosporin A treatment of steroid-refractory ulcerative colitis during pregnancy: report of two cases. Gut 2007; 56:1019.
34. Schnitzler F, Fidder HH, Ferrante M, et al. Intentional treatment with infliximab during pregnancy in women with inflammatory bowel disease [abstract]. Gastroenterology 2007; 132:A144.
35. Freeman K, Shao Z, Remzi FH, et al. Impact of orthotopic liver transplant for primary sclerosing cholangitis on chronic antibiotic refractory pouchitis. Clin Gastroenterol Hepatol 2008; 6:62-68.
36. Plevy S, Salzberg B, Van Assche G, et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 2007; 133:1414-1422.
37. Schreiber S, Keshavarzian A, Isaacs KL, et al. A randomized, placebocontrolled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 2007; 132:76-86.
38. Stremmel W, Ehehalt R, Autschbach F, Karner M. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med 2007; 147:603-610.
39. Musch E, Andus T, Malek M, et al. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta: an open long-term trial. Z Gastroenterol 2007; 45:1235-1240.
40. Schott E, Paul F, Wuerfel JT, et al. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a. World J Gastroenterol 2007; 13:3638-3640.
41. Goetz M, Atreya R, Ghalibafian M, et al. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007; 13:1365-1368.
42. Yang X, Stetsko D, Xie J, et al. Targeting T-cell costimulation with abatacept is effective in TNBS-induced colitis [abstract]. Gastroenterology 2007; 132: A153.
43. Nuding S, Fellermann K, Wehkamp J, Stange EF. Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 2007; 56:1240-1247.
44. Mallon P, McKay D, KirkS, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; (4):CD005573.
45. Turner D, Steinhart AH, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; (3):CD006443.
46. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657.
47. Mitsuyama K, Tomiyasu N, Masuda J, et al. High affinity of ecabet sodium for inflamed colonic mucosa in ulcerative colitis. Dig Dis Sci 2007; 52:1442-1443.
48. Onken JE, Greer PK, Calingaert B, Hale LP. Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. Clin Immunol 2008; 126:345-352.
49. Huber R, Ditfurth AV, Amann F, et al. Tormentil for active ulcerative colitis: an open-label, dose-escalating study. J Clin Gastroenterol 2007; 41:834-838.
50. Su C, Lewis JD, Goldberg B, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007; 132:516-526.
51. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132:763-786. 54 Reinisch W, Sandborn WJ, Bala M, et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13:1135-1140.
52. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007; 56:453-455.
53. Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133:412-422.
54. Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2007; 5:597-601.
55. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007; 13: 481 -489.
56. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10years. Gastroenterology 2007; 132:507-515.
57. Roberts SE, Williams JG, Yeates D, Goldacre MJ. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ 2007; 335:1033.
58. Stange EF, Travis SPL, Vermeire S, et al. European consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis 2008; 2:1 -23.
59. Travis SPL, Stange EF, Lémann M, et al. European consensus on the diagnosis and management of ulcerative colitis: current management. J Crohn's Colitis 2:24-62.
60. Biancone L, Michetti P, Travis SPL, et al. European consensus on the diagnosis and management of Crohn's disease: special situations. J Crohn's Colitis 2:63-92.
61. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflam Bowel Dis 2007; 13:1545-1553.
62. Society for Surgery of the Alimentary Tract. SSAT patient care guidelines: management of ulcerative colitis. J Gastrointest Surg 2007; 11:1203-1206.
63. Brown S, George B, Blakeborough A, et al. ACPGBI position statement on the management of acute severe colitis. Colorectal Dis (in press).